COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1
Status:
Not yet recruiting
Trial end date:
2021-08-31
Target enrollment:
Participant gender:
Summary
This is an open-label, controlled, single-centre pilot study of nivolumab in adult patients
with COVID-19. This clinical study aims to evaluate efficacy of anti-PD1 antibody in relation
to viral clearance and its safety.